Teva Pharmaceutical Industries Limited (TEVA) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
TEVA Revenue Growth
Revenue Breakdown (FY 2025)
TEVA's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
TEVA Revenue Analysis (2014–2025)
As of May 8, 2026, Teva Pharmaceutical Industries Limited (TEVA) generated trailing twelve-month (TTM) revenue of $17.35 billion, reflecting modest growth of +2.3% year-over-year. The most recent quarter (Q1 2026) recorded $3.98 billion in revenue, down 15.5% sequentially.
Looking at the longer-term picture, TEVA's 5-year compound annual growth rate (CAGR) stands at +0.7%, indicating moderate growth over time. The company achieved its highest annual revenue of $22.39 billion in 2017.
Revenue diversification analysis shows TEVA's business is primarily driven by Product (85%), Distribution Service (9%), and License (4%). With over half of revenue concentrated in Product, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including VTRS (+1.6% YoY), PRGO (-3.6% YoY), and AMRX (+8.0% YoY), TEVA has underperformed the peer group in terms of revenue growth. Compare TEVA vs VTRS →
TEVA Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| TEVACurrent | $17.3B | +2.3% | +0.7% | 12.5% | |
 VTRS | $14.3B | +1.6% | +3.7% | -18.6% | |
 PRGO | $4.3B | -3.6% | +0.8% | 8.1% | |
 AMRX | $3.0B | +8.0% | +8.7% | -0.2% | |
 SUPN | $719M | +16.3% | +6.7% | -5.1% | |
 LNTH | $1.5B | +0.6% | +35.3% | 20.2% |
TEVA Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $17.26B | +4.3% | $8.94B | 51.8% | $2.16B | 12.5% |
| 2024 | $16.54B | +4.4% | $8.06B | 48.7% | $-303,000,000 | -1.8% |
| 2023 | $15.85B | +6.2% | $7.64B | 48.2% | $433.0M | 2.7% |
| 2022 | $14.93B | -6.0% | $6.97B | 46.7% | $-2,197,000,000 | -14.7% |
| 2021 | $15.88B | -4.7% | $7.59B | 47.8% | $1.72B | 10.8% |
| 2020 | $16.66B | -1.4% | $7.73B | 46.4% | $-3,572,000,000 | -21.4% |
| 2019 | $16.89B | -10.4% | $7.54B | 44.6% | $-443,000,000 | -2.6% |
| 2018 | $18.85B | -15.8% | $8.30B | 44.0% | $-1,637,000,000 | -8.7% |
| 2017 | $22.39B | +2.2% | $10.82B | 48.4% | $-17,484,000,000 | -78.1% |
| 2016 | $21.90B | +11.5% | $11.86B | 54.1% | $2.15B | 9.8% |
Full TEVA Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See TEVA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TEVA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TEVA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonTEVA — Frequently Asked Questions
Quick answers to the most common questions about buying TEVA stock.
Is TEVA's revenue growth accelerating or slowing?
TEVA revenue growth slowed to +2.3%, below the 5-year CAGR of +0.7%. TTM revenue is $17.3B. The deceleration marks a shift from historical growth rates.
What is TEVA's long-term revenue growth rate?
Teva Pharmaceutical Industries Limited's 5-year revenue CAGR of +0.7% reflects the variable expansion pattern. Current YoY growth of +2.3% is near this long-term average.
How is TEVA's revenue distributed by segment?
TEVA reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.